News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
327,078 Results
Type
Article (19547)
Company Profile (139)
Press Release (307392)
Section
Business (105338)
Career Advice (863)
Deals (18515)
Drug Delivery (89)
Drug Development (50786)
Employer Resources (79)
FDA (7646)
Job Trends (7719)
News (185857)
Policy (17330)
Tag
Academia (732)
Alliances (27735)
Alzheimer's disease (550)
Approvals (7609)
Artificial intelligence (73)
Bankruptcy (170)
Best Places to Work (5465)
Biosimilars (65)
Biotechnology (61)
Cancer (457)
Cardiovascular disease (48)
Career advice (701)
Cell therapy (63)
Clinical research (41659)
Collaboration (168)
Compensation (57)
COVID-19 (1070)
Data (462)
Diabetes (81)
Diagnostics (1717)
Drug pricing (89)
Earnings (37946)
Employer resources (73)
Events (47490)
Executive appointments (158)
FDA (7863)
Funding (125)
Gene therapy (81)
GLP-1 (467)
Government (1794)
Healthcare (5877)
Infectious disease (1113)
Inflammatory bowel disease (67)
Interviews (114)
IPO (7292)
Job creations (2429)
Job search strategy (644)
Layoffs (250)
Legal (4077)
Lung cancer (88)
Manufacturing (107)
Medical device (1971)
Medtech (1974)
Mergers & acquisitions (11224)
Metabolic disorders (289)
Neuroscience (695)
NextGen Class of 2024 (2351)
Non-profit (901)
Northern California (542)
Obesity (191)
Opinion (171)
Patents (66)
People (32819)
Pharmaceutical (75)
Phase I (12993)
Phase II (17628)
Phase III (14193)
Pipeline (130)
Podcasts (53)
Policy (64)
Postmarket research (1609)
Preclinical (4543)
Radiopharmaceuticals (154)
Rare diseases (120)
Real estate (3190)
Regulatory (12111)
Research institute (817)
Resumes & cover letters (138)
Southern California (511)
Startups (2008)
United States (5155)
Vaccines (204)
Weight loss (174)
Date
Today (96)
Last 7 days (398)
Last 30 days (1455)
Last 365 days (18187)
2024 (15122)
2023 (19788)
2022 (26033)
2021 (26806)
2020 (24981)
2019 (20095)
2018 (15637)
2017 (17309)
2016 (16229)
2015 (18833)
2014 (14801)
2013 (12554)
2012 (13496)
2011 (13825)
2010 (12756)
Location
Africa (407)
Arizona (48)
Asia (25065)
Australia (3139)
California (1225)
Canada (670)
China (132)
Colorado (49)
Connecticut (48)
Europe (50306)
Florida (162)
Illinois (125)
Indiana (105)
Kansas (55)
Maryland (212)
Massachusetts (1040)
Minnesota (76)
New Jersey (488)
New York (369)
North Carolina (331)
Northern California (542)
Ohio (58)
Pennsylvania (315)
South America (603)
Southern California (511)
Texas (152)
Washington State (125)
327,078 Results for "suzhou kintor pharma".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Study of Kintor’s c-Myc Degrader Published in Subsidiary Journal of Nature
Kintor Pharmaceutical Limited announces that Kintor and its cooperative partner had published an article named MYC Induces CDK4/6 Inhibitors Resistance by Promoting pRB1 Degradation in a subsidiary journal of Nature—Nature Communications.
March 13, 2024
·
2 min read
Press Releases
Opening of Biosynth Biological Technology; a new Cutting-Edge Facility at Lifebay in Suzhou, China
October 30, 2024
·
2 min read
Drug Development
Kintor Pharma Announces the Approval for Phase II Clinical Trial of Hedgehog/SMO Inhibitor GT1708F for Treatment of IPF in China
Kintor Pharmaceutical Limited announced that its Hedgehog/SMO inhibitor GT1708F had obtained conditional approval to conduct Phase II clinical trial in China by the National Medical Products Administration for treatment of idiopathic pulmonary fibrosis.
October 11, 2023
·
2 min read
Business
Kintor Pharma Announces 2022 Annual Results and Recent Business Progress
Kintor Pharmaceutical Limited (Kintor Pharma, HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced business highlights and financial results for the year ended 31 December 2022.
March 30, 2023
·
8 min read
Drug Development
Kintor Pharma Announces Completion of Patient Enrollment in Phase II Clinical Trial of GT20029 for Treatment of Androgenetic Alopecia in China
Kintor Pharmaceutical Limited announced that the company has completed the enrollment of 180 patients for the Phase II clinical trial of its in-house developed first-in-class proteolysis targeting chimera compound GT20029 in China for the treatment of male androgenetic alopecia.
August 22, 2023
·
2 min read
Drug Development
Kintor Pharma Announces Successful Completion of Phase II Clinical Trial of KX-826 for Treatment of Androgenetic Alopecia in the US
Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, announced that the Phase II clinical trial of in-house developed KX-826 for the treatment of male androgenetic alopecia (“AGA”) in the US has been completed successfully.
May 11, 2023
·
3 min read
Drug Development
Kintor Pharma Announces Completion of First Patient Enrollment in Long-term Safety Phase III Trial of KX-826 for Treatment of AGA
Kintor Pharmaceutical Limited announced that the company has initiated the long-term safety trial (the “Long-term Safety Trial”) of KX-826, a potential first-in-class androgen receptor (AR) antagonist for the treatment of androgenetic alopecia (AGA) developed in-house, in China and has completed the first patient enrollment today.
July 19, 2023
·
2 min read
Drug Development
Kintor Pharma Announces Completion of Subject Enrollment in Phase III Clinical Trial of KX-826 for Treatment of Male Androgenetic Alopecia in China
Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939) announced that the company has completed the enrollment of 740 subjects recently for the Phase III clinical trial of its in-house developed first-in-class drug candidate KX-826 (pyrilutamide) in China for the treatment of male androgenetic alopecia (AGA) adults.
March 28, 2023
·
4 min read
Drug Development
Kintor Pharma Announces Positive Top-line U.S. Phase I Trial Results of GT20029, the World’s First Topical Use PROTAC Compound
Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, announced the positive top-line results from the U.S. Phase I clinical trial of GT20029, a Kintor Pharma in-house developed and fully owned proteolysis targeting chimera (PROTAC) compound.
February 10, 2023
·
4 min read
Biotech Beach
Longbio Pharma Presented Positive Phase 1 Results for LP-003 at 2024AAD
Longbio Pharma (Suzhou) Co., Ltd. proudly announced the Phase I data of LP-003 (new generation of anti-IgE antibody) at the 2024 American Academy of Dermatology Association annual meeting (2024AAD).
March 12, 2024
·
3 min read
1 of 32,708
Next